
Quarterly report 2022-Q4
added 02-09-2023
Cardiovascular Systems EBITDA 2011-2026 | CSII
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -32.1 M | -8.84 M | -23.8 M | 2.62 M | 6.17 M | 2.59 M | -41.8 M | -30.3 M | -32.1 M | -21.4 M | -13.6 M | -8.09 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.17 M | -41.8 M | -16.7 M |
Quarterly EBITDA Cardiovascular Systems
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.18 M | -10 M | -17.6 M | -9.3 M | -8.21 M | -7.16 M | -14.8 M | -5.34 M | 587 K | -933 K | 1.76 M | -2.4 M | -3.04 M | -5.19 M | -1.88 M | -5.19 M | 439 K | -2.17 M | 1.96 M | -2.17 M | -275 K | -758 K | 1.71 M | -758 K | 1.08 M | -910 K | 3.02 M | -910 K | -15.1 M | -12.3 M | -13.3 M | -12.3 M | -5.25 M | -7.82 M | -4.5 M | -7.82 M | -7.5 M | -6.55 M | -7.39 M | -6.82 M | -5.12 M | -5.17 M | -5.12 M | -5.21 M | -3.66 M | -3.06 M | -3.66 M | -3.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.02 M | -17.6 M | -4.95 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
IRIDEX Corporation
IRIX
|
-8.91 M | $ 1.35 | - | $ 21.8 M | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Orthofix Medical
OFIX
|
-4.11 M | $ 11.72 | -1.26 % | $ 464 M | ||
|
LENSAR
LNSR
|
-7.7 M | $ 5.56 | -8.4 % | $ 64 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
AxoGen
AXGN
|
-1.19 M | $ 32.61 | 2.71 % | $ 1.5 B | ||
|
CONMED Corporation
CNMD
|
120 M | $ 36.56 | -0.19 % | $ 1.13 B | ||
|
Penumbra
PEN
|
207 M | $ 334.17 | -0.41 % | $ 13 B | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Electromed
ELMD
|
10.7 M | $ 24.7 | 0.86 % | $ 209 M | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Insulet Corporation
PODD
|
564 M | $ 225.5 | -0.7 % | $ 15.9 B | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
-15.2 M | $ 0.7 | 3.3 % | $ 38.1 M | ||
|
Aethlon Medical
AEMD
|
-9 M | $ 2.16 | -6.09 % | $ 3.37 M | ||
|
Profound Medical Corp.
PROF
|
-30.3 M | $ 5.15 | -4.63 % | $ 180 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Quanterix Corporation
QTRX
|
-110 M | $ 3.82 | -3.05 % | $ 163 M | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 11.48 | 10.7 % | $ 1.55 B | ||
|
Myomo
MYO
|
-13.5 M | $ 0.7 | -1.83 % | $ 29.3 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
-61 M | $ 2.4 | -1.64 % | $ 141 M | ||
|
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
-18 M | $ 3.91 | 4.83 % | $ 146 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 15.91 | -3.4 % | $ 373 M | ||
|
Outset Medical
OM
|
-62.4 M | $ 3.53 | -2.35 % | $ 53.7 K | ||
|
Inspire Medical Systems
INSP
|
64.9 M | $ 52.07 | -0.17 % | $ 1.53 B | ||
|
Sintx Technologies
SINT
|
-10.4 M | $ 2.57 | 0.78 % | $ 7.13 M | ||
|
Pulmonx Corporation
LUNG
|
-52.6 M | $ 1.31 | -5.76 % | $ 53.3 M | ||
|
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
Sensus Healthcare
SRTS
|
-9.91 M | $ 3.96 | -3.65 % | $ 64.7 M | ||
|
InspireMD
NSPR
|
426 M | $ 1.79 | 3.47 % | $ 115 M | ||
|
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | ||
|
NuVasive
NUVA
|
147 M | - | - | $ 2.07 B | ||
|
Second Sight Medical Products
EYES
|
-24.3 M | - | -0.97 % | $ 54.4 M |